100+ datasets found
  1. f

    Dataset for: Bioinformatory-assisted analysis of next-generation sequencing...

    • wiley.figshare.com
    xlsx
    Updated Jun 3, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Linnéa Marielena Malgerud; Johan Lindberg; Valttteri Wirta; Maria Gustavsson-Liljefors; Masoud Karimi; Carlos Fernandez-Moro; Katrin Stecker; Alexander Picker; Caroline Huelsewig; Martin Stein; Regina Bohnert; Marco Del Chiaro; Stephan L. Haas; Rainer L. Heuchel; Johan Permert; Markus J. Mäurer; Stephan Brock; Caroline Verbeke; Lars Engstrand; David B. Jackson; Henrik Grönberg; Matthias Lohr (2023). Dataset for: Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer [Dataset]. http://doi.org/10.6084/m9.figshare.5311114.v1
    Explore at:
    xlsxAvailable download formats
    Dataset updated
    Jun 3, 2023
    Dataset provided by
    Wiley
    Authors
    Linnéa Marielena Malgerud; Johan Lindberg; Valttteri Wirta; Maria Gustavsson-Liljefors; Masoud Karimi; Carlos Fernandez-Moro; Katrin Stecker; Alexander Picker; Caroline Huelsewig; Martin Stein; Regina Bohnert; Marco Del Chiaro; Stephan L. Haas; Rainer L. Heuchel; Johan Permert; Markus J. Mäurer; Stephan Brock; Caroline Verbeke; Lars Engstrand; David B. Jackson; Henrik Grönberg; Matthias Lohr
    License

    CC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
    License information was derived automatically

    Description

    Pancreatic ductal adenocarcinoma (PDAC) is a tumor with an extremely poor prognosis, predominantly due to chemotherapy resistance and numerous somatic mutations. Consequently, PDAC is a prime candidate for the use of sequencing to identify causative mutations, facilitating subsequent administration of targeted therapy. In a feasibility study, we retrospectively assessed the therapeutic recommendations of a novel, evidence-based software that analyzes Next-generation sequencing (NGS) data using a large panel of pharmacogenomic biomarkers for efficacy and toxicity. Tissue from 14 patients with PDAC was sequenced using NGS with a 620 gene panel. FASTQ files were fed into the TreatmentMAP software. The results were compared with chemotherapy in the patients, including all side effects. No changes in therapy were made. Known driver mutations for PDAC were confirmed, e.g. KRAS, TP53. Software analysis revealed positive biomarkers for predicted effective and ineffective treatments in all patients. At least one biomarker associated with increased toxicity could be detected in all patients. Patients had been receiving one of the currently approved chemotherapy agents. In two patients, toxicity could have been correctly predicted by the software analysis. Results suggest NGS, in combination with an evidence-based software, could be conducted within a two-week period - thus being feasible for clinical routine. Therapy recommendations were principally off-label use. Based on the predominant KRAS mutations, other drugs were predicted to be ineffective. The pharmacogenomic biomarkers indicative of increased toxicity could be retrospectively linked to reported negative side effects in the respective patients. Finally, the occurrence of somatic and germline mutations in cancer syndrome-associated genes is noteworthy, despite a high frequency of these particular variants in the background population. These results suggest software-analysis of NGS data provides evidence-based information on effective, ineffective, and toxic drugs, potentially forming the basis for precision cancer medicine in PDAC.

  2. D

    Global Medical Imaging Software Market – Industry Trends and Forecast to...

    • databridgemarketresearch.com
    Updated Dec 2022
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Data Bridge Market Research (2022). Global Medical Imaging Software Market – Industry Trends and Forecast to 2030 [Dataset]. https://www.databridgemarketresearch.com/reports/global-medical-imaging-software-market
    Explore at:
    Dataset updated
    Dec 2022
    Dataset authored and provided by
    Data Bridge Market Research
    License

    https://www.databridgemarketresearch.com/privacy-policyhttps://www.databridgemarketresearch.com/privacy-policy

    Time period covered
    2023 - 2030
    Area covered
    Global
    Description

    Report Metric

    Details

    Forecast Period

    2023 to 2030

    Base Year

    2022

    Historic Years

    2021 (Customizable to 2015 - 2020)

    Quantitative Units

    Revenue in USD Billion, Volumes in Units, Pricing in USD

    Segments Covered

    Imaging Type (2D Imaging, 3D Imaging, 4D Imaging), Application (Dental Applications, Orthopedic Applications, Cardiology Applications, Obstetrics and Gynecology Applications, Mammography Applications, Urology and Nephrology Applications), End-User (Hospitals, Diagnostic Centers)

    Countries Covered

    U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

    Market Players Covered

    Koninklijke Philips N.V. (Netherlands), RamSoft, Inc. (Canada), InHealth Group (U.K.), Radiology Reports online (U.S.), Siemens (Germany), Sonic Healthcare Limited (Australia), RadNet, Inc. (U.S.), General Electric (U.S.), Akumin Inc. (U.S.), Hologic Inc. (U.S.), Shimadzu Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), CANON MEDICAL SYSTEMS CORPORATION (Japan), Carl Zeiss Ag (Germany), FUJIFILM Corporation (Japan), Hitachi, Ltd. (Japan), MEDNAX Services, Inc. (U.S.), Carestream Health (U.S), Teleradiology Solutions (U.S.), UNILABS (Switzerland), ONRAD, Inc. (U.S.)

    Market Opportunities

    • Advancements in imaging technology
  3. MDR (Medical Device Reporting)

    • catalog.data.gov
    • healthdata.gov
    • +2more
    Updated Mar 16, 2021
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    U.S. Food and Drug Administration (2021). MDR (Medical Device Reporting) [Dataset]. https://catalog.data.gov/dataset/mdr-medical-device-reporting
    Explore at:
    Dataset updated
    Mar 16, 2021
    Dataset provided by
    Food and Drug Administrationhttp://www.fda.gov/
    Description

    This database allows you to search the CDRH's database information on medical devices which may have malfunctioned or caused a death or serious injury during the years 1992 through 1996.

  4. EMRBots: a 100,000-patient database

    • figshare.com
    zip
    Updated Sep 3, 2018
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Uri Kartoun (2018). EMRBots: a 100,000-patient database [Dataset]. http://doi.org/10.6084/m9.figshare.7040198.v1
    Explore at:
    zipAvailable download formats
    Dataset updated
    Sep 3, 2018
    Dataset provided by
    Figsharehttp://figshare.com/
    Authors
    Uri Kartoun
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    A 100,000-patient database that contains in total 100,000 virtual patients, 361,760 admissions, and 107,535,387 lab observations.

  5. m

    Medical Carts Market Report, Share | CAGR of 12.7%

    • market.us
    csv, pdf
    Updated Feb 6, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Market.us (2024). Medical Carts Market Report, Share | CAGR of 12.7% [Dataset]. https://market.us/report/medical-carts-market/
    Explore at:
    csv, pdfAvailable download formats
    Dataset updated
    Feb 6, 2024
    Dataset provided by
    Market.us
    License

    https://market.us/privacy-policy/https://market.us/privacy-policy/

    Time period covered
    2022 - 2032
    Area covered
    Global
    Description
    Table of Contents

    Report Overview

    The Global Medical Carts Market size is expected to be worth around USD 7.1 Billion by 2033, from USD 2.1 Billion in 2023, growing at a CAGR of 12.7% during the forecast period from 2024 to 2033.

    Read More

  6. R

    Computer Vision for Medication Blister Classification Dataset

    • universe.roboflow.com
    zip
    Updated Aug 4, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    KNOK (2023). Computer Vision for Medication Blister Classification Dataset [Dataset]. https://universe.roboflow.com/knok/computer-vision-for-medication-blister-classification
    Explore at:
    zipAvailable download formats
    Dataset updated
    Aug 4, 2023
    Dataset authored and provided by
    KNOK
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Variables measured
    Number Of Drags In Blister Bounding Boxes
    Description

    Project Overview: The goal of this project is to develop a computer vision system that can accurately classify medication blisters as either full or empty. This system will aid in automating the verification process of medication blister packs, ensuring the correct dispensing of medications in healthcare settings. By leveraging machine learning techniques and image analysis algorithms, the system will be trained on a dataset of labeled images to achieve high accuracy in blister classification.

    Class Types:

    Full Blister: This class represents medication blisters that contain the intended number of pills or capsules. Images labeled as "full" will be used as positive examples during the training phase.

    Empty Blister: This class represents medication blisters that do not contain any pills or capsules. Images labeled as "empty" will serve as negative examples during training.

  7. Replacement of conventional treatment with alternative medecine in France...

    • statista.com
    Updated Aug 25, 2021
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Statista (2021). Replacement of conventional treatment with alternative medecine in France 2019 [Dataset]. https://www.statista.com/statistics/1101910/medicine-non-conventional-perception-france-replacement-treatment/
    Explore at:
    Dataset updated
    Aug 25, 2021
    Dataset authored and provided by
    Statistahttp://statista.com/
    Time period covered
    Oct 16, 2019 - Oct 25, 2019
    Area covered
    France
    Description

    This statistic represents the breakdown of French people giving up a treatment prescribed by a conventional doctor to replace it by an alternative medicine treatment in 2019. It shows that the majority of respondents, 74 percent, had not given up following a treatment prescribed by a doctor to replace it with an alternative medicine treatment.

    Alternative medicine, also called complementary or integrative medicine among others, designates therapeutic practices residing outside classical medical science which originated from oriental, ancestral or innovative traditions. Among those alternative medicines, we can for example find acupuncture (from Chinese medicine), Ayurvedic medicine, herbal medicine, osteopathy or homeopathy.

  8. Data from: Unified Medical Language System (UMLS)

    • healthdata.gov
    • datadiscovery.nlm.nih.gov
    • +4more
    application/rdfxml +5
    Updated Mar 31, 2021
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    datadiscovery.nlm.nih.gov (2021). Unified Medical Language System (UMLS) [Dataset]. https://healthdata.gov/dataset/Unified-Medical-Language-System-UMLS-/r8sj-79df
    Explore at:
    csv, tsv, application/rssxml, json, application/rdfxml, xmlAvailable download formats
    Dataset updated
    Mar 31, 2021
    Dataset provided by
    National Institutes of Healthhttp://www.nih.gov/
    Description

    The UMLS integrates and distributes key terminology, classification and coding standards, and associated resources to promote creation of more effective and interoperable biomedical information systems and services, including electronic health records.

  9. H

    Medical Terahertz Technology Market by Type, Application & Regional |...

    • futuremarketinsights.com
    csv, pdf
    Updated Nov 28, 2022
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Future Market Insights (2022). Medical Terahertz Technology Market by Type, Application & Regional | Forecast 2022 to 2032 [Dataset]. https://www.futuremarketinsights.com/reports/medical-terahertz-technology-market
    Explore at:
    csv, pdfAvailable download formats
    Dataset updated
    Nov 28, 2022
    Dataset authored and provided by
    Future Market Insights
    License

    https://www.futuremarketinsights.com/privacy-policyhttps://www.futuremarketinsights.com/privacy-policy

    Time period covered
    2022 - 2032
    Area covered
    Worldwide
    Description

    The global medical terahertz technology market is valued at US$ 135.29 Million in 2022 and is projected to grow at a CAGR of 17.1% during the forecast period, reaching a value of US$ 768.05 Million by 2032.

    AttributeDetails
    Medical Terahertz Technology Market Size Value in 2022US$ 135.29 Million
    Medical Terahertz Technology Market Forecast Value in 2032US$ 768.05 Million
    Medical Terahertz Technology Market CAGR Global Growth Rate (2022 to 2032)17.1%

    Scope of Report

    AttributeDetails
    Forecast Period2022 to 2032
    Historical Data Available for2018 to 2022
    Market AnalysisUS$ Billion for Value and MT for Volume
    Key Regions CoveredNorth America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa
    Key Countries CoveredUSA, Canada, Brazil, Mexico, Chile, Peru, Germany, United Kingdom., Spain, Italy, France, Russia, Poland, China, India, Japan, Australia, New Zealand, GCC Countries, North Africa, South Africa, and Turkey
    Key Segments Covered
    • Type
    • Application
    • Region
    Key Companies Profiled
    • Acal Bfi Limited
    • Advantest Corporation
    • Teraview limited
    • Luna Innovations Inc.
    • Insight Product Company
    • Toptica Photonics AG
    • HUBNER GmbH & Co. KG
    • Terasense Group Inc.
    • Microtech Instrument Inc.
    • Menlo Systems GmbH
    Report CoverageMarket Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
    Customization & PricingAvailable upon Request
  10. Medicine Dataset

    • kaggle.com
    zip
    Updated Sep 25, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    rjain777 (2023). Medicine Dataset [Dataset]. https://www.kaggle.com/datasets/rjain777/medicine-dataset
    Explore at:
    zip(15137894 bytes)Available download formats
    Dataset updated
    Sep 25, 2023
    Authors
    rjain777
    Description

    Dataset

    This dataset was created by rjain777

    Contents

  11. Medical Image Analysis Software Market by Type and Geography - Forecast and...

    • technavio.com
    Updated Apr 18, 2021
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Technavio (2021). Medical Image Analysis Software Market by Type and Geography - Forecast and Analysis 2021-2025 [Dataset]. https://www.technavio.com/report/medical-image-analysis-software-market-industry-analysis
    Explore at:
    Dataset updated
    Apr 18, 2021
    Dataset provided by
    TechNavio
    Authors
    Technavio
    License

    https://www.technavio.com/content/privacy-noticehttps://www.technavio.com/content/privacy-notice

    Time period covered
    2021 - 2025
    Area covered
    Global
    Description

    Snapshot img

    The medical image analysis software market has the potential to grow by USD 1.53 billion during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 7.90%.

    This medical image analysis software market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers market segmentation by type (standalone and integrated) and geography (North America, APAC, Europe, South America, and MEA). The medical image analysis software market report also offers information on several market vendors, including Agfa-Gevaert NV, AnalyzeDirect Inc., AQUILAB SAS, Carestream Health Inc., Esaote SpA, General Electric Co., International Business Machines Corp., Koninklijke Philips NV, Mirada Medical Ltd., and Siemens AG among others.

    What will the Medical Image Analysis Software Market Size be in 2021?

    Browse TOC and LoE with selected illustrations and example pages of Medical Image Analysis Software Market

    Get Your FREE Sample Now!

    Medical Image Analysis Software Market: Key Drivers and Trends

    Based on our research output, there has been a positive impact on the market growth during and post COVID-19 era. The advances in the medical imaging field is notably driving the medical image analysis software market growth, although factors such as growing concerns regarding data privacy and security may impede market growth. To unlock information on the key market drivers and the COVID-19 pandemic impact on the medical image analysis software industry get your FREE report sample now.

          The emergence of advanced technologies in medical imaging is a major factor driving the demand for medical imaging systems.
          With advanced research and technological evolution, medical imaging has seen numerous advances in technology.
          Open and portable MRIs, big data and analytics, and 3D technologies in diagnostic radiology are some of the latest advances that have increased the capabilities of medical imaging systems.
          Digital mammography has revolutionized breast cancer screening by providing greater detail and can generate results that are similar to conventional mammograms but without using film and X-rays.
          From the use of big data in medical imaging to the possibilities of 3D imaging, these advances are changing the future of medical imaging and leading to increased adoption of different medical imaging techniques.
    
    
    
    
          As the occurrence of chronic diseases increases in the population worldwide, there will be an increased use of medical imaging techniques and high demand for image analysis for improved diagnoses.
          The growing prevalence of chronic diseases and generally incurable conditions, such as cancer, cardiovascular conditions, diabetes, and asthma, is responsible for the increase in demand for medical imaging systems.
          Post-imaging analysis using advanced image analysis software helps in the early detection of chronic diseases and assesses the effectiveness of therapy on patients. 
          Medical imaging technology plays a major role in addressing chronic health concerns, as it helps in focusing on preventative health.
          Diagnostic imaging plays a crucial role in the early detection of chronic diseases and in monitoring disease progression. 
    

    This medical image analysis software market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. Get detailed insights on the trends and challenges, which will help companies evaluate and develop growth strategies.

    Who are the Major Medical Image Analysis Software Market Vendors?

    The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

    Agfa-Gevaert NV
    AnalyzeDirect Inc.
    AQUILAB SAS
    Carestream Health Inc.
    Esaote SpA
    General Electric Co.
    International Business Machines Corp.
    Koninklijke Philips NV
    Mirada Medical Ltd.
    Siemens AG
    

    The medical image analysis software market is fragmented and the vendors are deploying growth strategies such as creating awareness about the benefits of using medical image analysis software to compete in the market. Click here to uncover other successful business strategies deployed by the vendors.

    To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

    Download a free sample of the medical image analysis software market forecast report for insights on complete key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

    Which are the Key Regions for Medical Image Analysis Software

  12. Biomarker technologies: global market forecast 2024 and 2029

    • statista.com
    Updated Nov 29, 2017
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Matej Mikulic (2017). Biomarker technologies: global market forecast 2024 and 2029 [Dataset]. https://www.statista.com/topics/4345/personalized-medicine/
    Explore at:
    Dataset updated
    Nov 29, 2017
    Dataset provided by
    Statistahttp://statista.com/
    Authors
    Matej Mikulic
    Description

    This statistic shows forecasts for the global biomarker market in 2024 and 2029. By the year 2029, the market for biomarker technologies is expected to increase up to 88 billion U.S. dollars. Biomarkers are biomolecules present in blood, other bodily fluids, or tissues indicating either a normal or abnormal physiological process, or the presence of a condition or illness.

  13. E

    Estonian Medical Prescription Center

    • healthinformationportal.eu
    • www-test.healthinformationportal.eu
    html
    Updated Sep 7, 2022
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Estonian Health Insurance Fund (2022). Estonian Medical Prescription Center [Dataset]. https://www.healthinformationportal.eu/health-information-sources/estonian-medical-prescription-center
    Explore at:
    htmlAvailable download formats
    Dataset updated
    Sep 7, 2022
    Dataset provided by
    The Estonian Health Insurance Fund
    Authors
    Estonian Health Insurance Fund
    Area covered
    Estonia
    Variables measured
    sex, title, topics, country, language, data_owners, description, geo_coverage, contact_email, free_keywords, and 7 more
    Measurement technique
    Registry data
    Description

    The prescription center is an electronic database for issuing and processing prescriptions (for medicines, baby foods, medical devices).

  14. p

    Asia Medical Imaging Informatics Market - Persistence Market Research

    • persistencemarketresearch.com
    csv, pdf
    Updated May 17, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Persistence Market Research (2023). Asia Medical Imaging Informatics Market - Persistence Market Research [Dataset]. https://www.persistencemarketresearch.com/market-research/asia-medical-imaging-informatics-market.asp
    Explore at:
    csv, pdfAvailable download formats
    Dataset updated
    May 17, 2023
    Dataset authored and provided by
    Persistence Market Research
    License

    https://www.persistencemarketresearch.com/privacy-policy.asphttps://www.persistencemarketresearch.com/privacy-policy.asp

    Time period covered
    2024 - 2034
    Area covered
    Worldwide
    Description

    The global Asia Medical Imaging Informatics Market market size exceeded USD 5.15 billion in 2022 and is slated to register 15.5% CAGR between 2023 and 2033

  15. r

    The New England Journal of Medicine Abbreviation ISO4 - ResearchHelpDesk

    • researchhelpdesk.org
    Updated Feb 23, 2022
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Research Help Desk (2022). The New England Journal of Medicine Abbreviation ISO4 - ResearchHelpDesk [Dataset]. https://www.researchhelpdesk.org/journal/abbreviation/392/the-new-england-journal-of-medicine
    Explore at:
    Dataset updated
    Feb 23, 2022
    Dataset authored and provided by
    Research Help Desk
    Description

    The New England Journal of Medicine Abbreviation ISO4 - ResearchHelpDesk - The New England Journal of Medicine (NEJM) is the world’s leading medical journal and website. Published continuously for over 200 years, NEJM delivers high-quality, peer-reviewed research and interactive clinical content to physicians, educators, and the global medical community. Our mission is to bring physicians the best research and information at the intersection of biomedical science and clinical practice and to present this information in understandable and clinically useful formats that inform health care delivery and improve patient outcomes. To these ends, the NEJM editorial team employs rigorous: Editorial, peer, and statistical review processes to evaluate manuscripts for scientific accuracy, novelty, and importance. Policies and practices to ensure that authors disclose all relevant financial associations and that such associations in no way influence the content NEJM publishes. A truly global brand, NEJM keeps health care professionals at the leading edge of medical knowledge, helps them to gain broad understanding in their areas of interest, and provides valuable perspectives on the practice of medicine. Today, NEJM is the most widely read, cited, and influential general medical periodical in the world. More than 600,000 people from nearly every country read NEJM in print and online each week. Each year, NEJM receives more than 16,000 research and other submissions for consideration for publication. About 5% of original research submissions achieve publication by NEJM; more than half originate from outside the U.S. NEJM is cited more often in scientific literature than any other medical journal, and has the highest Journal Impact Factor (70.670) of all general medical journals (2018 Journal Citation Reports, Web of Science Group, 2019). NEJM is a Public Access Journal. All original research content is freely available on NEJM.org six months after the date of publication. In addition, qualifying low-income countries are granted free access to all articles on NEJM.org dating back to 1990. The editors may also make certain materials including articles on global health and of public health importance free to all readers immediately upon publication on NEJM.org

  16. d

    DSS Medical Benefit Plan Participation CY 2012-2023

    • catalog.data.gov
    • data.ct.gov
    Updated Mar 16, 2024
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    data.ct.gov (2024). DSS Medical Benefit Plan Participation CY 2012-2023 [Dataset]. https://catalog.data.gov/dataset/dss-medical-benefit-plan-participation-cy-2012-2019
    Explore at:
    Dataset updated
    Mar 16, 2024
    Dataset provided by
    data.ct.gov
    Description

    In order to facilitate public review and access, enrollment data published on the Open Data Portal is provided as promptly as possible after the end of each month or year, as applicable to the data set. Due to eligibility policies and operational processes, enrollment can vary slightly after publication. Please be aware of the point-in-time nature of the published data when comparing to other data published or shared by the Department of Social Services, as this data may vary slightly. As a general practice, for monthly data sets published on the Open Data Portal, DSS will continue to refresh the monthly enrollment data for three months, after which time it will remain static. For example, when March data is published the data in January and February will be refreshed. When April data is published, February and March data will be refreshed, but January will not change. This allows the Department to account for the most common enrollment variations in published data while also ensuring that data remains as stable as possible over time. In the event of a significant change in enrollment data, the Department may republish reports and will notate such republication dates and reasons accordingly. In March 2020, Connecticut opted to add a new Medicaid coverage group: the COVID-19 Testing Coverage for the Uninsured. Enrollment data on this limited-benefit Medicaid coverage group is being incorporated into Medicaid data effective January 1, 2021. Enrollment data for this coverage group prior to January 1, 2021, was listed under State Funded Medical. An historical accounting of enrollment of the specific coverage group starting in calendar year 2020 will also be published separately. The data represents number of active recipients who received benefits under a medical benefit plan in that calendar year. A recipient may have received benefits from multiple plans in the same year; if so that recipient will be included in multiple categories in this dataset (counted more than once.) For privacy considerations, a count of zero is used for counts less than five. NOTE: On April 22, 2019 the methodology for determining HUSKY A Newborn recipients changed, which caused an increase of recipients for that benefit starting in October 2016. We now count recipients recorded in the ImpaCT system as well as in the HIX system for that assistance type, instead using HIX exclusively. Also, the methodology for determining the address of the recipients changed: 1. The address of a recipient in the ImpaCT system is now correctly determined specific to that month instead of using the address of the most recent month. This resulted in some shuffling of the recipients among townships starting in October 2016. 2. If, in a given month, a recipient has benefit records in both the HIX system and in the ImpaCT system, the address of the recipient is now calculated as follows to resolve conflicts: Use the residential address in ImpaCT if it exists, else use the mailing address in ImpaCT if it exists, else use the address in HIX. This resulted in a reduction in counts for most townships starting in March 2017 because a single address is now used instead of two when the systems do not agree. NOTE: On February 14 2019, the enrollment counts for 2012-2015 across all programs were updated to account for an error in the data integration process. As a result, the count of the number of people served increased by 13% for 2012, 10% for 2013, 8% for 2014 and 4% for 2015. Counts for 2016, 2017 and 2018 remain unchanged. NOTE: On 11/30/2018 the counts were revised because of a change in the way active recipients were counted in one source system.

  17. Epidemiology & Medical Statistics Unit (EMSU) National Proficiency Testing...

    • data.gov.uk
    • ckan.publishing.service.gov.uk
    • +2more
    Updated Dec 12, 2013
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Health and Safety Executive (2013). Epidemiology & Medical Statistics Unit (EMSU) National Proficiency Testing Council (NPTC) [Dataset]. https://www.data.gov.uk/dataset/655d531b-21d9-428e-9b31-1ee30110d8c8/epidemiology-medical-statistics-unit-emsu-national-proficiency-testing-council-nptc
    Explore at:
    Dataset updated
    Dec 12, 2013
    Dataset authored and provided by
    Health and Safety Executivehttps://www.hse.gov.uk/
    License

    https://www.data.gov.uk/dataset/655d531b-21d9-428e-9b31-1ee30110d8c8/epidemiology-medical-statistics-unit-emsu-national-proficiency-testing-council-nptc#licence-infohttps://www.data.gov.uk/dataset/655d531b-21d9-428e-9b31-1ee30110d8c8/epidemiology-medical-statistics-unit-emsu-national-proficiency-testing-council-nptc#licence-info

    Description

    Used for inputting, retention, retrieval and analysis of medical data collection on workers exposed to pesticides. Number of records in dataset – 85,900. Contains sensitive medical in confidence data and personal data.

  18. F

    Consumer Price Index for All Urban Consumers: Services Less Medical Care...

    • fred.stlouisfed.org
    json
    Updated Apr 10, 2024
    + more versions
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    (2024). Consumer Price Index for All Urban Consumers: Services Less Medical Care Services in U.S. City Average [Dataset]. https://fred.stlouisfed.org/series/CUUR0000SASL5
    Explore at:
    jsonAvailable download formats
    Dataset updated
    Apr 10, 2024
    License

    https://fred.stlouisfed.org/legal/#copyright-public-domainhttps://fred.stlouisfed.org/legal/#copyright-public-domain

    Area covered
    United States
    Description

    Graph and download economic data for Consumer Price Index for All Urban Consumers: Services Less Medical Care Services in U.S. City Average (CUUR0000SASL5) from Mar 1957 to Mar 2024 about medical, urban, consumer, services, CPI, inflation, price index, indexes, price, and USA.

  19. B

    Dataset 2: Interrupted time-series results

    • borealisdata.ca
    tsv
    Updated Mar 16, 2023
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Borealis (2023). Dataset 2: Interrupted time-series results [Dataset]. http://doi.org/10.5683/SP2/PNNQNO
    Explore at:
    tsv(1832)Available download formats
    Dataset updated
    Mar 16, 2023
    Dataset provided by
    Borealis
    License

    CC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
    License information was derived automatically

    Description

    All results of the primary interrupted time-series results evaluating targeted and total border closures that met the following criteria: 1) at least seven days of data is available before and after the intervention point, 2) for multiple intervention time series, at least seven days has passed since the last intervention point, and 3) for multiple sequential targeted border closures, the second (or third) intervention is observed to indicate an increase of at least 20% of the world’s population being targeted by the new border closures.

  20. Medical condition reporting transactions

    • data.qld.gov.au
    • researchdata.edu.au
    csv, txt
    Updated Jan 10, 2024
    Share
    FacebookFacebook
    TwitterTwitter
    Email
    Click to copy link
    Link copied
    Close
    Cite
    Transport and Main Roads (2024). Medical condition reporting transactions [Dataset]. https://www.data.qld.gov.au/dataset/medical-condition-reporting-transactions
    Explore at:
    txt(1024), csv(126259)Available download formats
    Dataset updated
    Jan 10, 2024
    Dataset provided by
    Department of Transport and Main Roadshttp://tmr.qld.gov.au/
    License

    Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
    License information was derived automatically

    Description

    Number of medical condition transactions in Queensland by month and transaction type.

Share
FacebookFacebook
TwitterTwitter
Email
Click to copy link
Link copied
Close
Cite
Linnéa Marielena Malgerud; Johan Lindberg; Valttteri Wirta; Maria Gustavsson-Liljefors; Masoud Karimi; Carlos Fernandez-Moro; Katrin Stecker; Alexander Picker; Caroline Huelsewig; Martin Stein; Regina Bohnert; Marco Del Chiaro; Stephan L. Haas; Rainer L. Heuchel; Johan Permert; Markus J. Mäurer; Stephan Brock; Caroline Verbeke; Lars Engstrand; David B. Jackson; Henrik Grönberg; Matthias Lohr (2023). Dataset for: Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer [Dataset]. http://doi.org/10.6084/m9.figshare.5311114.v1

Dataset for: Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer

Related Article
Explore at:
xlsxAvailable download formats
Dataset updated
Jun 3, 2023
Dataset provided by
Wiley
Authors
Linnéa Marielena Malgerud; Johan Lindberg; Valttteri Wirta; Maria Gustavsson-Liljefors; Masoud Karimi; Carlos Fernandez-Moro; Katrin Stecker; Alexander Picker; Caroline Huelsewig; Martin Stein; Regina Bohnert; Marco Del Chiaro; Stephan L. Haas; Rainer L. Heuchel; Johan Permert; Markus J. Mäurer; Stephan Brock; Caroline Verbeke; Lars Engstrand; David B. Jackson; Henrik Grönberg; Matthias Lohr
License

CC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
License information was derived automatically

Description

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with an extremely poor prognosis, predominantly due to chemotherapy resistance and numerous somatic mutations. Consequently, PDAC is a prime candidate for the use of sequencing to identify causative mutations, facilitating subsequent administration of targeted therapy. In a feasibility study, we retrospectively assessed the therapeutic recommendations of a novel, evidence-based software that analyzes Next-generation sequencing (NGS) data using a large panel of pharmacogenomic biomarkers for efficacy and toxicity. Tissue from 14 patients with PDAC was sequenced using NGS with a 620 gene panel. FASTQ files were fed into the TreatmentMAP software. The results were compared with chemotherapy in the patients, including all side effects. No changes in therapy were made. Known driver mutations for PDAC were confirmed, e.g. KRAS, TP53. Software analysis revealed positive biomarkers for predicted effective and ineffective treatments in all patients. At least one biomarker associated with increased toxicity could be detected in all patients. Patients had been receiving one of the currently approved chemotherapy agents. In two patients, toxicity could have been correctly predicted by the software analysis. Results suggest NGS, in combination with an evidence-based software, could be conducted within a two-week period - thus being feasible for clinical routine. Therapy recommendations were principally off-label use. Based on the predominant KRAS mutations, other drugs were predicted to be ineffective. The pharmacogenomic biomarkers indicative of increased toxicity could be retrospectively linked to reported negative side effects in the respective patients. Finally, the occurrence of somatic and germline mutations in cancer syndrome-associated genes is noteworthy, despite a high frequency of these particular variants in the background population. These results suggest software-analysis of NGS data provides evidence-based information on effective, ineffective, and toxic drugs, potentially forming the basis for precision cancer medicine in PDAC.

Search
Clear search
Close search
Google apps
Main menu